The Canadian Intellectual Property Office has released a proposed new section of Chapter 17 (Biotechnology and Medicinal Inventions) of its Manual of Patent Office Practice (MOPOP), on the examination of pharmaceutical solid forms such as polymorphs, salts, hydrates, solvates, desolvates and co-crystals.
Consultation on the new MOPOP section is open until August 10, 2018.
Related Publications & Articles
-
Health Canada seeks input on new draft guidance for co-packaged drug products
On March 18, 2025, Health Canada released a Notice that it is seeking feedback on a draft guidance on co-packaged drug products.Read More -
Canada’s Drug Agency releases 2025 Watch List highlighting AI technologies in health care
On March 25, 2025, Canada’s Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada...Read More -
Health Canada publishes Guide to the precision regulating authorities under the Food and Drugs Act
In March 2025, Health Canada published a Guide to the precision regulating authorities under the Food and Drugs Act.Read More